1.	Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 60 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CLTR0310-301, NCT01696084
2.	A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 0812010140, NCT00875693
3.	Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2642.00, NCI-2013-00481, P30CA015704, NCT01804101